Section
Private equity, IPOs, mergers, and capital markets.
The agreement positions J&J at the frontier of a gene-delivery approach that could reshape autoimmune treatment without the complexity of cell harvesting.
The Oxford-based cancer immunotherapy specialist will gain a US public listing through a deal that rescues Neuphoria's stranded shareholders.
The triple-G agonist achieved 22.6% weight loss in phase 3 trials, yet failed to confirm the cardiovascular risk reduction investors had anticipated.
The sodium channel-targeting drugmaker's public market debut signals growing investor appetite for non-addictive pain therapeutics.
A new annual accolade will honour outstanding healthcare leadership, with the winner unveiled at a major December event.
A spike in American physician practice insolvencies signals systemic stress that international investors and UK-listed health groups cannot ignore.
BMS deepens its Nvidia partnership to accelerate drug discovery with an AI infrastructure play that could reshape R&D timelines.
The AI-driven diagnostics firm absorbs its oncology genomics partner three years after their initial collaboration.
Soficitinib meets its primary endpoint in nonsegmental vitiligo, advancing a crowded race for the first approved TYK2 therapy in the condition.
Deals of $100 million or more are dominating venture capital flows into digital health, reshaping who benefits and who gets left behind.
Lipfendra's clearance marks a landmark shift in cardiovascular medicine and raises questions for UK prescribing pathways.
A proposed US fee schedule reduction for 2027 carries lessons for UK healthcare markets navigating similar value-versus-volume tensions.
Eli Lilly's latest acquisition marks the most significant mainstream validation yet for psychedelic-derived psychiatric treatments.
A deep-dive on the forces driving healthcare mergers and acquisitions through 2024–2025 — from private equity's pivot to add-ons and physician platforms, to the drag of elevated interest rates, tighter antitrust scrutiny, and where the next wave of deals is likely to land.